Effect of timolol on refractive outcomes in eyes with myopic regression after
laser in situ keratomileusis: a prospective randomized clinical trial.
Author(s): Shojaei A, Eslani M, Vali Y, Mansouri M, Dadman N, Yaseri M.
Affiliation(s): Research Department, Basir Eye Center, Tehran, Iran.
Publication date & source: 2012, Am J Ophthalmol. , 154(5):790-798
PURPOSE: To compare the effects of timolol on refractive outcomes in eyes with
myopic regression after laser in situ keratomileusis (LASIK) with a
control-matched group.
DESIGN: Prospective, randomized, parallel-controlled, double-masked clinical
trial. A computer-generated randomization list based on random block permutation
(length 4 to 8) was used for treatment allocation.
METHODS: setting: Basir Eye Center, Tehran, Iran. Patient population: Of 124 eyes
with myopic regression after LASIK using Technolas 217-Z, 45 eyes in each group
were analyzed. Intervention: Patients were randomly assigned into either Group 1,
who received timolol 0.5% eye drops, or Group 2, who received artificial tears
for 6 months. Main outcome measure: Spherical equivalent (SE) at 6 months
posttreatment.
RESULTS: In Group 1, SE improved from -1.48 ± 0.99 diopter (D) before treatment
to -0.88 ± 0.91 D and -0.86 ± 0.93 D 6 months after treatment and 6 months after
timolol discontinuation, respectively (P < .001). In Group 2, it was -1.57 ± 0.67
D, -1.83 ± 0.76 D, and -1.91 ± 0.70 D, respectively (P < .001). SE was
significantly better in Group 1 6 months after treatment and 6 months after
discontinuation of treatment (P < .001 for both comparisons). There was a 0.26 D
decrease in SE improvement every 4 months after the surgery in the Group 1 (P <
.001).
CONCLUSIONS: Timolol application is effective for the treatment of myopic
regression after LASIK compared with control group. Its effects last for at least
6 months after its discontinuation.
|
